Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)expressing metastatic colorectal cancer (mCRC) in the first-line setting: a phase II study

Cervantes, A., Humblet, Y., Casac, E., Van Cutsem, E., Sastre, J., André, T., Van Laethem, J., Zubel, A., Gascon, N., & de Gramont, A. (2005). Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)expressing metastatic colorectal cancer (mCRC) in the first-line setting: a phase II study. EJC - Supplements, 3(2), 181-182. (Original work published 2005)